8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

   PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

                                DECEMBER 16, 2003
                Date of Report (date of Earliest Event Reported)


                                 ISOLAGEN, INC.
             (Exact Name of Registrant as Specified in its Charter)


            DELAWARE                       0-12666              87-0458888
(State or Other Jurisdiction of     (Commission File No.)    (I.R.S. Employer
 Incorporation or Organization)                             Identification No.)


                 2500 WILCREST, 5TH FLOOR, HOUSTON, TEXAS 77042
              (Address of principal executive offices and zip code)

                                 (713) 780-4754
              (Registrant's telephone number, including area code)


                                 NOT APPLICABLE
          (Former name or former address, if changed from last report)



ITEM 5.  OTHER EVENTS.

         On December 16, 2003 the Company issued a press release relating to
manufacturing system breakthrough. The press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference. The reader is advised to
read the press release in its entirety.



                          [THE SIGNATURE PAGE FOLLOWS.]


                                       2



                                    SIGNATURE

         Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                               ISOLAGEN, INC.


Date:    December 16, 2003                     By:  /s/ Jeffrey W. Tomz
                                                    ---------------------------
                                                    Chief Financial Officer


                                       3

EX-99.1

                                                                   EXHIBIT 99.1


TUESDAY, DECEMBER 16, 2003, IMMEDIATE RELEASE

PRESS RELEASE

SOURCE:  Isolagen, Inc.

ISOLAGEN SHOWS MANUFACTURING SYSTEM BREAKTHROUGH

HOUSTON, T.X. - (PRNewswire) - December 16, 2003 - Isolagen, Inc. (AMEX: ILE), a
biopharmaceutical company specializing in the development and commercialization
of autologous cellular therapy for hard and soft tissue regeneration, is pleased
to announce that it has developed a new cell culturing system and automated
manufacturing system as part of its manufacturing cost reduction efforts.

Through the Company's collaboration with Applikon Biotechnology, a leader in
acoustic biotechnology where they use sound waves to separate cells from culture
medium in bioreactors for both research and production, the Company has
developed a new system that permits a fully automated cell harvesting process in
a closed loop sterile system compared to the existing process of separating
cells utilizing centrifuge technology. This modification of Applikon's system
should result in significant cost reduction and allow the Company to move toward
a platform that enables mass production.

"We are excited about our collaboration with Isolagen and anticipate a mutually
beneficial relationship for both companies," stated, Christine Corsette,
Director of New Product Development at Applikon Biotechnology.

Michael Macaluso, CEO, stated, "Historically, autologous cell companies have
been hampered by manufacturing technologies that use an outdated methodology for
culturing cells through the utilization of plastic flasks. This methodology is
labor intensive and slow and, as a result, imbedded with high costs. Our focus
over the last 27 months has been to automate our culturing system using newer
technology common to the pharmaceutical and other industries to streamline our
process. We have been collaborating with Applikon under a Joint Intellectual
Property Collaboration that allows Isolagen to patent its manufacturing system
improvements beyond Applikon's existing patents. This new system should reduce
our costs significantly and allow for pricing flexibility to address the
individual marketplaces."

ABOUT ISOLAGEN, INC.

Isolagen, Inc. (AMEX: ILE) is the parent company of Isolagen Technologies, Inc.,
which was founded in 1995. Isolagen has focused its efforts in the development
of autologous cellular technology that has specific applications in cosmetic
dermatology and is exploring applications for periodontal disease,
reconstructive dentistry and other health-related markets.


                                       4



Autologous cellular therapy is a process whereby a patient's own cells are
extracted, reproduced and then reintroduced to the patient for specific cosmetic
and medical applications. Unlike other applications for the treatment of dermal
defects, Isolagen utilizes only the patient's unique, living cells to produce
the patient's own collagen. There is no foreign substance utilized in this
treatment protocol. Isolagen's goal is to become the industry leader in the
research, development and commercialization of autologous cellular therapy.

This press release contains forward-looking statements and general statements
relating to the development of autologous cellular therapy that has specific
applications in cosmetic dermatology and also relating to the exploration of
applications for periodontal disease, reconstructive dentistry and other
health-related markets. The discovery and development of applications for
autologous cellular therapy are subject to substantial risks and uncertainties.
There can be no assurance that Isolagen's clinical trials relating to autologous
cellular therapy applications for the treatment of dermal defects or gingival
recession can be conducted within the timeframe that Isolagen expects, that such
trials will yield positive results, or that additional applications for the
commercialization of autologous cellular therapy can be identified and advanced
into human clinical trials. These and other factors, including, but not limited
to those described in Isolagen's most recent annual report on Form 10-KSB/A
filed with the Securities and Exchange Commission, could cause future results to
differ materially from the expectations expressed in this press release. The
forward-looking statements contained in this press release may become outdated
over time. Isolagen does not assume any responsibility for updating any
forward-looking statements.

Isolagen's corporate headquarters are located in Houston, TX. For further
information, please see www.isolagen.com.

Contact:
Isolagen, Inc.
Michael Macaluso, CEO 713-780-4754
Jeffrey W. Tomz, CFO 713-780-4754


                                       5